Magna Labs has been named as an inaugural member of the Merck Digital Sciences Studio (MDSS) — a collaboration between Merck, Microsoft for Startups and the New Jersey Innovation Institute to back innovative biotech and digital health startups, including investment from Merck Global Health Innovation Fund LLC, Northpond Ventures and McKesson Ventures.
This presents a huge opportunity to accelerate our low-code bioinformatics testing and benchmarking software into the biopharma arena, driving quality in computational innovation starting from the earliest stages of research and drug discovery up to diagnostics and therapeutic selection.Well-measured, high quality bio-software ensures both scientists and patients reach better outcomes faster. Thank you to theand MDSS team for supporting our mission to promote the precision of precision medicine!
The MDSS is a collaboration between Merck, Microsoft for Startups, and the New Jersey Innovation Institute, a New Jersey Institute of Technology (NJIT) subsidiary. This 10-month startup accelerator program with direct investments from Merck Global Health Innovation Fund, Northpond Ventures, and McKesson Ventures will empower members and enable the generation of innovative digital technologies for drug discovery and development through hands-on mentorship, connection opportunities with industry leading partners, and training in an active entrepreneurial setting. The program includes workshops, mentorship, coaching, subsidized office space, and access to Microsoft's Founders Hub resources, including Azure Cloud computing credits.
The collaborative cohort located in Newark, New Jersey and Cambridge, Massachusetts will focus on important and disruptive biotechnical approaches in artificial intelligence (AI) and machine learning (ML), with expertise and tools from clinical scientists to continue Merck’s mission to strengthen the life-sciences ecosystem.